WallStreetZenWallStreetZen

NASDAQ: IMUX
Immunic Inc Stock

$1.30+0.02 (+1.56%)
Updated Mar 27, 2024
IMUX Price
$1.30
Fair Value Price
$3.04
Market Cap
$116.91M
52 Week Low
$0.95
52 Week High
$3.11
P/E
-0.62x
P/B
4.04x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$93.61M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.88
Operating Cash Flow
-$71M
Beta
1.1
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A

IMUX Overview

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IMUX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

IMUX ($1.30) is undervalued by 57.23% relative to our estimate of its Fair Value price of $3.04 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
IMUX ($1.30) is significantly undervalued by 57.23% relative to our estimate of its Fair Value price of $3.04 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
IMUX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IMUX due diligence checks available for Premium users.

Be the first to know about important IMUX news, forecast changes, insider trades & much more!

IMUX News

Valuation

IMUX fair value

Fair Value of IMUX stock based on Discounted Cash Flow (DCF)
Price
$1.30
Fair Value
$3.04
Undervalued by
57.23%
IMUX ($1.30) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IMUX ($1.30) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IMUX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

IMUX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.62x
Industry
14.3x
Market
44.45x

IMUX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.04x
Industry
6.2x
IMUX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

IMUX's financial health

Profit margin

Revenue
$0.0
Net Income
-$21.6M
Profit Margin
0%
IMUX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$54.3M
Liabilities
$25.4M
Debt to equity
0.88
IMUX's short-term assets ($52.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMUX's short-term assets ($52.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMUX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IMUX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$14.0M
Investing
-$165.0k
Financing
$604.0k
IMUX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

IMUX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
IMUX$116.91M+1.56%-0.62x4.04x
CLRB$117.27M-5.58%-1.17x-86.48x
MCRB$117.79M+3.72%-0.88x-2.63x
VIGL$118.03M+14.70%-1.50x1.02x
ORMP$114.26M+3.68%20.14x0.70x

Immunic Stock FAQ

What is Immunic's quote symbol?

(NASDAQ: IMUX) Immunic trades on the NASDAQ under the ticker symbol IMUX. Immunic stock quotes can also be displayed as NASDAQ: IMUX.

If you're new to stock investing, here's how to buy Immunic stock.

What is the 52 week high and low for Immunic (NASDAQ: IMUX)?

(NASDAQ: IMUX) Immunic's 52-week high was $3.11, and its 52-week low was $0.95. It is currently -58.2% from its 52-week high and 37.57% from its 52-week low.

How much is Immunic stock worth today?

(NASDAQ: IMUX) Immunic currently has 89,929,016 outstanding shares. With Immunic stock trading at $1.30 per share, the total value of Immunic stock (market capitalization) is $116.91M.

Immunic stock was originally listed at a price of $480.00 in Apr 17, 2014. If you had invested in Immunic stock at $480.00, your return over the last 9 years would have been -99.73%, for an annualized return of -48.15% (not including any dividends or dividend reinvestments).

How much is Immunic's stock price per share?

(NASDAQ: IMUX) Immunic stock price per share is $1.30 today (as of Mar 27, 2024).

What is Immunic's Market Cap?

(NASDAQ: IMUX) Immunic's market cap is $116.91M, as of Mar 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Immunic's market cap is calculated by multiplying IMUX's current stock price of $1.30 by IMUX's total outstanding shares of 89,929,016.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.